Alterations to Melanocortinergic, GABAergic and Cannabinoid Neurotransmission Associated with Olanzapine-Induced Weight Gain

BACKGROUND/AIM: Second generation antipsychotics (SGAs) are used to treat schizophrenia but can cause serious metabolic side-effects, such as obesity and diabetes. This study examined the effects of low to high doses of olanzapine on appetite/metabolic regulatory signals in the hypothalamus and brai...

Descripción completa

Detalles Bibliográficos
Autores principales: Weston-Green, Katrina, Huang, Xu-Feng, Deng, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306411/
https://www.ncbi.nlm.nih.gov/pubmed/22438946
http://dx.doi.org/10.1371/journal.pone.0033548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306411/
https://www.ncbi.nlm.nih.gov/pubmed/22438946
http://dx.doi.org/10.1371/journal.pone.0033548

Ejemplares similares